Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.50 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.50 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.50 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.50 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.50 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.50 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.50 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.50 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.50 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.50 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.35 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.34 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27633583 | 1.00 | GABRA1 (0.50) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL40096 | 0.98 | GABRA1 (0.52) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL3902884 | 0.95 | GABRA1 (0.50) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL2146165 | 0.87 | GABRA5 (0.41) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL2146778 | 0.87 | GABRA5 (0.41) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL1464969 | 0.87 | GABRA5 (0.41) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Trifluoroacetic Acid SCHEMBL17372956 | 0.85 | GABRP (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL2148728 | 0.84 | GABRA5 (0.43) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL2146012 | 0.84 | GABRA5 (0.43) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL2672481 | 0.84 | GABRA5 (0.43) | GABRA1TSHRGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2025-10-14 | — | — | US | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4380930-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2271646-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| WO-2009123986-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | WO | disclosed |
| CN-100491361-C | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |
| EP-1608365-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | Sucampo AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004087138-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| EP-0177078-A1 | Spasmolytically active tertiary amine derivatives and method of preparing the same | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | TP53, CASP3, BAX | GABRA1 4145/4885GABRG2 3272/4885GABRB3 3427/4885 |
| US-20110077235-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAX, BCL2, BAD | GABRA1 4538/4885GABRG2 4736/4885GABRB3 4682/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | GABRA1 518/4885GABRG2 929/4885GABRB3 918/4885 |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC11, HDAC3 | GABRA1 3342/4885GABRG2 4387/4885GABRB3 2585/4885 |
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | GABRA1 4380/4885GABRG2 3907/4885GABRB3 4128/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | GABRA1 1222/4885GABRG2 1249/4885GABRB3 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.